CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
rhNGF 20 µg/mL +1 moredrug
Likely dose
rhNGF 20 µg/mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02101281
NCT02101281Phase 2Completed
CompareCT.gov

An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye

Dompé Farmaceutici S.p.A·interventional·Posted Apr 2, 2014·Updated Apr 19, 2024

In Brief

A Phase 2 clinical trial evaluating rhNGF 20 µg/mL and rhNGF 4 µg/mL for Dry Eye Syndrome. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The primary objective of this study was to assess the efficacy and safety of different doses of rhNGF when administered as eye drops to patients with dry eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndrome
CountriesAustria
CollaboratorsCross Research S.A.

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2, 2014
Enrollment StartJan 20, 2014
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.3 years ago

Interventions

rhNGF 20 µg/mLdrug

1 drop for each eye, twice daily for 28 day

rhNGF 4 µg/mLdrug

1 drop each eye, twice daily for 28 day